Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 1Recruiting 1Completed 1Available 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Dermatologic 5Thoracic 1Head & Neck 1

Conditions

Melanoma 5Skin Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma, Cutaneous Malignant 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × lifileucel × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Available
Dermatologic

Melanoma

NCT07288203 2026-04-20

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.

Phase 2 Active not recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics, Inc.

Phase 3 Recruiting
670 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT02360579 2026-03-25

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed
220 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡